The combination of CA125 and HE4 with, or without, other biomarkers such as Glycodelin, Plau-R, MUC-1, PAI-1 (Havrilesky et al, 2008), SMRP (Hellström and Hellström, 2008; Moore et al, 2008a), CA72-4, and osteopontin (Moore et al, 2008a) has been evaluated to improve ovarian cancer diagnosis. This evidence concerns the gene MUC16 and ovarian carcinoma.